Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Inks Distribution Deal with Fluxion Biosciences

NEW YORK (GenomeWeb News) – Molecular Devices today announced a global distribution agreement with Fluxion Biosciences covering its IonFlux instruments and consumables.

Molecular Devices also is providing support for all IonFlux Systems users as part of the deal, it said.

Financial and other terms of the deal were not disclosed.

South San Francisco, Calif.-based Fluxion provides tools for cellular analysis. Its portfolio includes instruments for live cell imaging and the analysis of circulating tumor cells. The Ion Flux is for automated patch clamping.

Sunnyvale, Calif.-based Molecular Devices is a Danaher company and provides bioanalytical measurement systems, software, and consumables, including products for high-throughput screening, and genomic and cellular analysis.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.